vs

Side-by-side financial comparison of CLOVER HEALTH INVESTMENTS, CORP. (CLOV) and Sotera Health Co (SHC). Click either name above to swap in a different company.

CLOVER HEALTH INVESTMENTS, CORP. is the larger business by last-quarter revenue ($487.7M vs $303.4M, roughly 1.6× Sotera Health Co). Sotera Health Co runs the higher net margin — 11.5% vs -10.1%, a 21.6% gap on every dollar of revenue. On growth, CLOVER HEALTH INVESTMENTS, CORP. posted the faster year-over-year revenue change (44.7% vs 4.6%). Sotera Health Co produced more free cash flow last quarter ($52.4M vs $-69.0M). Over the past eight quarters, CLOVER HEALTH INVESTMENTS, CORP.'s revenue compounded faster (18.6% CAGR vs 10.6%).

Clover Health Investments, Corp. is an American health care company founded in 2014. The company provides Medicare Advantage (MA) insurance plans and operates as a direct contracting entity with the U.S. government. The company manages care for Medicare beneficiaries in 11 states and started trading publicly on January 8, 2021.

Sotera Health Co is a global provider of end-to-end medical safety solutions. It offers sterilization services, analytical laboratory testing, and regulatory advisory support for medical device manufacturers, pharmaceutical firms, and food and consumer product companies, helping clients meet industry standards and ensure product safety for end users worldwide.

CLOV vs SHC — Head-to-Head

Bigger by revenue
CLOV
CLOV
1.6× larger
CLOV
$487.7M
$303.4M
SHC
Growing faster (revenue YoY)
CLOV
CLOV
+40.2% gap
CLOV
44.7%
4.6%
SHC
Higher net margin
SHC
SHC
21.6% more per $
SHC
11.5%
-10.1%
CLOV
More free cash flow
SHC
SHC
$121.4M more FCF
SHC
$52.4M
$-69.0M
CLOV
Faster 2-yr revenue CAGR
CLOV
CLOV
Annualised
CLOV
18.6%
10.6%
SHC

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CLOV
CLOV
SHC
SHC
Revenue
$487.7M
$303.4M
Net Profit
$-49.3M
$34.8M
Gross Margin
54.7%
Operating Margin
-10.1%
23.2%
Net Margin
-10.1%
11.5%
Revenue YoY
44.7%
4.6%
Net Profit YoY
-123.2%
182.8%
EPS (diluted)
$0.12

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CLOV
CLOV
SHC
SHC
Q4 25
$487.7M
$303.4M
Q3 25
$496.6M
$311.3M
Q2 25
$477.6M
$294.3M
Q1 25
$462.3M
$254.5M
Q4 24
$337.0M
$290.2M
Q3 24
$331.0M
$285.5M
Q2 24
$356.3M
$276.6M
Q1 24
$346.9M
$248.2M
Net Profit
CLOV
CLOV
SHC
SHC
Q4 25
$-49.3M
$34.8M
Q3 25
$-24.4M
$48.4M
Q2 25
$-10.6M
$8.0M
Q1 25
$-1.3M
$-13.3M
Q4 24
$-22.1M
$12.3M
Q3 24
$-9.2M
$17.0M
Q2 24
$7.4M
$8.8M
Q1 24
$-19.2M
$6.3M
Gross Margin
CLOV
CLOV
SHC
SHC
Q4 25
54.7%
Q3 25
57.0%
Q2 25
56.6%
Q1 25
53.2%
Q4 24
56.6%
Q3 24
24.5%
55.4%
Q2 24
30.3%
55.2%
Q1 24
23.6%
51.2%
Operating Margin
CLOV
CLOV
SHC
SHC
Q4 25
-10.1%
23.2%
Q3 25
-4.9%
23.4%
Q2 25
-2.2%
6.4%
Q1 25
-0.3%
-5.8%
Q4 24
-6.4%
30.0%
Q3 24
-2.7%
28.2%
Q2 24
2.0%
27.8%
Q1 24
-6.5%
21.4%
Net Margin
CLOV
CLOV
SHC
SHC
Q4 25
-10.1%
11.5%
Q3 25
-4.9%
15.5%
Q2 25
-2.2%
2.7%
Q1 25
-0.3%
-5.2%
Q4 24
-6.6%
4.2%
Q3 24
-2.8%
6.0%
Q2 24
2.1%
3.2%
Q1 24
-5.5%
2.5%
EPS (diluted)
CLOV
CLOV
SHC
SHC
Q4 25
$0.12
Q3 25
$0.17
Q2 25
$0.03
Q1 25
$-0.05
Q4 24
$0.05
Q3 24
$0.06
Q2 24
$0.03
Q1 24
$0.02

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CLOV
CLOV
SHC
SHC
Cash + ST InvestmentsLiquidity on hand
$78.3M
$344.6M
Total DebtLower is stronger
$2.1B
Stockholders' EquityBook value
$308.7M
$606.0M
Total Assets
$541.0M
$3.3B
Debt / EquityLower = less leverage
3.53×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CLOV
CLOV
SHC
SHC
Q4 25
$78.3M
$344.6M
Q3 25
$299.2M
Q2 25
$332.4M
Q1 25
$304.4M
Q4 24
$194.5M
$277.2M
Q3 24
$288.0M
$306.7M
Q2 24
$254.8M
$246.1M
Q1 24
$208.3M
$261.1M
Total Debt
CLOV
CLOV
SHC
SHC
Q4 25
$2.1B
Q3 25
$2.1B
Q2 25
$2.2B
Q1 25
$2.2B
Q4 24
$2.2B
Q3 24
$2.2B
Q2 24
$2.2B
Q1 24
$2.2B
Stockholders' Equity
CLOV
CLOV
SHC
SHC
Q4 25
$308.7M
$606.0M
Q3 25
$340.9M
$550.5M
Q2 25
$344.2M
$511.3M
Q1 25
$336.1M
$414.1M
Q4 24
$341.1M
$404.9M
Q3 24
$342.2M
$470.2M
Q2 24
$324.9M
$422.8M
Q1 24
$292.5M
$429.4M
Total Assets
CLOV
CLOV
SHC
SHC
Q4 25
$541.0M
$3.3B
Q3 25
$559.7M
$3.2B
Q2 25
$575.0M
$3.2B
Q1 25
$583.7M
$3.1B
Q4 24
$580.7M
$3.1B
Q3 24
$653.0M
$3.1B
Q2 24
$674.2M
$3.1B
Q1 24
$671.8M
$3.1B
Debt / Equity
CLOV
CLOV
SHC
SHC
Q4 25
3.53×
Q3 25
3.89×
Q2 25
4.34×
Q1 25
5.36×
Q4 24
5.49×
Q3 24
4.73×
Q2 24
5.26×
Q1 24
5.19×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CLOV
CLOV
SHC
SHC
Operating Cash FlowLast quarter
$-66.9M
$103.1M
Free Cash FlowOCF − Capex
$-69.0M
$52.4M
FCF MarginFCF / Revenue
-14.1%
17.3%
Capex IntensityCapex / Revenue
0.4%
16.7%
Cash ConversionOCF / Net Profit
2.96×
TTM Free Cash FlowTrailing 4 quarters
$-69.2M
$149.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CLOV
CLOV
SHC
SHC
Q4 25
$-66.9M
$103.1M
Q3 25
$12.1M
$71.2M
Q2 25
$5.4M
$57.4M
Q1 25
$-16.3M
$55.5M
Q4 24
$34.8M
$55.7M
Q3 24
$50.0M
$97.5M
Q2 24
$44.8M
$61.3M
Q1 24
$25.9M
$9.7M
Free Cash Flow
CLOV
CLOV
SHC
SHC
Q4 25
$-69.0M
$52.4M
Q3 25
$11.4M
$35.0M
Q2 25
$4.8M
$26.2M
Q1 25
$-16.5M
$35.6M
Q4 24
$33.3M
$-10.2M
Q3 24
$49.6M
$61.1M
Q2 24
$44.4M
$19.4M
Q1 24
$25.5M
$-25.2M
FCF Margin
CLOV
CLOV
SHC
SHC
Q4 25
-14.1%
17.3%
Q3 25
2.3%
11.2%
Q2 25
1.0%
8.9%
Q1 25
-3.6%
14.0%
Q4 24
9.9%
-3.5%
Q3 24
15.0%
21.4%
Q2 24
12.5%
7.0%
Q1 24
7.3%
-10.2%
Capex Intensity
CLOV
CLOV
SHC
SHC
Q4 25
0.4%
16.7%
Q3 25
0.1%
11.6%
Q2 25
0.1%
10.6%
Q1 25
0.0%
7.8%
Q4 24
0.5%
22.7%
Q3 24
0.1%
12.7%
Q2 24
0.1%
15.2%
Q1 24
0.1%
14.1%
Cash Conversion
CLOV
CLOV
SHC
SHC
Q4 25
2.96×
Q3 25
1.47×
Q2 25
7.21×
Q1 25
Q4 24
4.52×
Q3 24
5.73×
Q2 24
6.04×
7.00×
Q1 24
1.53×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CLOV
CLOV

Segment breakdown not available.

SHC
SHC

Transferred At Point In Time$198.4M65%
Nelson Labs$55.2M18%
Nordion$49.8M16%

Related Comparisons